Brucellosis in Wildlife: Implications for Livestock and Human Health

Introduction

Brucellosis is a globally distributed zoonotic disease caused by Gram-negative, facultative intracellular bacteria of the genus Brucella. In domestic livestock, the disease manifests primarily as reproductive failure: abortion, retained placenta, orchitis, and reduced milk yield. The economic burden on cattle, sheep, goat, and swine industries is substantial and well documented [1, 2]. However, maintaining brucellosis eradication in livestock faces a persistent challenge: wildlife reservoirs. In North America, Brucella abortus infection in free-ranging bison (Bison bison) and elk (Cervus canadensis) in the Greater Yellowstone Ecosystem (GYE) represents a critical obstacle to eradication in domestic cattle herds [3, 4]. Similar wildlife-livestock interfaces occur globally, including African buffalo (Syncerus caffer) harboring B. abortus and wild boar (Sus scrofa) carrying B. suis [5, 6].

This article examines the biological, diagnostic, and epidemiological dimensions of brucellosis in wildlife, with emphasis on B. abortus in bison and elk. It details serological diagnostic methods, the role of the wildlife-livestock interface in pathogen maintenance and spillover, and barriers to wildlife vaccination. The review is framed within a One Health perspective that integrates veterinary medicine, molecular diagnostics, and computational epidemiology.

Pathogen Biology and Host Range

Brucella species are facultative intracellular pathogens that preferentially replicate within macrophages, dendritic cells, and placental trophoblasts [7]. The key virulence factor is the type IV secretion system (T4SS) encoded by the virB operon, which delivers effector proteins that modulate host cell signaling and inhibit apoptosis [8]. Brucella lipopolysaccharide (LPS) is a smooth (S) type in wild-type strains; the O-polysaccharide side chain is both a major antigen and a target for serological diagnosis [9]. Rough mutants lacking the O-chain are attenuated and form the basis for some live vaccines (e.g., RB51), but such vaccines fail to induce antibodies detectable by standard O-chain serology [10].

The host range varies by species. Brucella abortus primarily infects cattle and other bovids but also infects bison and elk. Brucella suis biovar 1 infects wild boar and feral swine, while Brucella melitensis infects sheep and goats, with spillover to wildlife such as ibex and chamois in Europe [5, 11]. Brucella ovis causes epididymitis in sheep but is not zoonotic. Cross-species transmission between wildlife and livestock is documented at the GYE interface for B. abortus and in the Mediterranean basin for B. melitensis [12, 13].

Wildlife Reservoirs and Maintenance Hosts

Bison and Elk in the Greater Yellowstone Ecosystem

The GYE harbors the largest remaining free-ranging bison population in North America and over 100,000 elk. Seroprevalence of B. abortus antibodies in bison varies by herd and management area, ranging from 30% to 60% in sampled populations [3, 14]. Elk in the same region show lower but still significant seroprevalence (10% to 30%), with winter feeding grounds serving as hotspots for aggregation and transmission [15]. Bison are considered maintenance hosts: infection persists within bison populations without continued input from cattle. Elk, in contrast, may act as spillover hosts that amplify transmission when high densities occur on feedgrounds [16].

Transmission occurs predominantly through contact with aborted fetuses, fetal membranes, and vaginal discharges. The pathogen can survive for weeks in the environment under cool, moist conditions, facilitating indirect transmission at common grazing or watering sites [17]. Experimental studies have shown that intraruminal inoculation of B. abortus in bison reproduces abortion and bacterial shedding, confirming that wildlife can propagate the pathogen in naive populations [18].

Other Wildlife Species

Wild boar and feral swine are reservoirs for B. suis across Europe, Australia, and parts of the Americas. B. suis in feral swine has spilled over into domestic pig operations and is a significant zoonotic risk for hunters and abattoir workers [6]. In Africa, African buffalo are maintenance hosts for B. abortus, and interactions with cattle at shared waterholes drive transmission [19]. Reindeer and caribou (Rangifer tarandus) in the Arctic carry B. suis biovar 4, which causes disease in humans and dogs [20]. In the Mediterranean, B. melitensis circulates in free-ranging sheep and goats and has been detected in red deer and wild boar [21].

Diagnostic Serology in Wildlife

Diagnosis of brucellosis in wildlife relies primarily on serological detection of antibodies against Brucella LPS O-polysaccharide. Direct culture is fastidious, requires BSL-3 facilities, and has low sensitivity in chronically infected animals. Molecular detection by PCR on tissues (lymph nodes, spleen, fetal stomach contents) is increasingly used but faces challenges of sample inhibition and low bacterial loads in latent infections [22, 23].

Rose Bengal Test (RBPT)

The Rose Bengal test (RBPT) is a rapid, inexpensive agglutination assay using stained Brucella abortus cells at pH 3.6 to detect anti-O-chain antibodies. It is widely used as a screening test in cattle and is adapted for serum and plasma from wildlife [24]. Sensitivity is high (95%) in acute cases but declines in chronic infections. False positives occur due to cross-reactions with Yersinia enterocolitica O:9, Escherichia coli O:157, and other Gram-negative bacteria [25]. Standardization for bison and elk has been performed, but cutoff interpretation requires validation in the target species [26].

Competitive ELISA (cELISA)

Competitive enzyme-linked immunosorbent assays (cELISA) use monoclonal antibodies directed against Brucella O-polysaccharide epitopes. The test is more specific than RBPT because it reduces cross-reactivity from non-specific antibodies (e.g., from Yersinia infection) [27]. The cELISA is the confirmatory test recommended by the World Organisation for Animal Health (WOAH) for international trade. In wildlife, cELISA has been validated for bison, elk, and African buffalo [28]. However, sensitivity may be lower in wild boar for B. suis due to antigenic variation in the LPS [29].

Other Serological Methods

The complement fixation test (CFT) remains a WOAH-prescribed test but is technically demanding and subject to anticomplementary activity in wildlife sera [30]. The fluorescence polarization assay (FPA) is a homogeneous, rapid method that measures the rotational movement of fluorescently labeled O-polysaccharide beads in the presence of antibodies. FPA has shown good performance for B. abortus in bison and elk [31]. The indirect ELISA (iELISA) using protein conjugates (e.g., cytoplasmic protein extracts) offers an alternative to LPS-based tests and may reduce cross-reactivity [32].

Table 1: Comparison of serological tests for Brucella abortus in wildlife

Diagnostic Workflow

The following Mermaid diagram illustrates a typical serological diagnostic algorithm for brucellosis surveillance in wildlife populations.

flowchart TD
    A[Wildlife serum sample], > B{RBPT screening}
    B, >|Negative| C[Report as negative]
    B, >|Positive| D[cELISA confirmatory]
    D, >|Positive| E[Confirmed seropositive]
    D, >|Negative| F[Discordant result]
    F, > G[Option: FPA or iELISA]
    G, >|Positive| E
    G, >|Negative| H[Resample and retest]
    H, > B

In field surveillance, a two-tiered approach (RBPT followed by cELISA) is standard for bison and elk in the GYE [33]. Confirmatory cELISA eliminates most cross-reactions. Discordant results (RBPT positive, cELISA negative) should prompt further testing with FPA or iELISA. For research or high-throughput screening, cELISA alone may be used to reduce labor.

Wildlife-Livestock Interface and Transmission Dynamics

The probability of B. abortus transmission from wildlife to livestock is a function of three variables: pathogen prevalence in the wildlife population, contact rate at the interface, and infectiousness of shedding animals. In the GYE, bison and elk migrate seasonally onto private and public grazing lands where cattle are present [34]. Experimental models and empirical data show that elk particularly are responsible for a majority of cattle infections because their large aggregations on feedgrounds produce high contamination of the environment [35]. Bison, though individually more infectious, have lower contact rates with cattle due to intensive management and hazing [36].

Spatial risk models have identified areas of high spillover probability near feedgrounds in Wyoming and Montana. Serological typing of B. abortus isolates using multiple-locus variable-number tandem repeat analysis (MLVA) and whole-genome sequencing confirms that strains circulating in wildlife are genetically indistinguishable from those in nearby cattle, supporting spillover events [37, 38].

In Africa, the interface is often around protected areas where buffalo and cattle share water points. A study in the Kruger to Canyons Biosphere found that cattle adjacent to buffalo populations had 2.4 times higher odds of brucellosis than those with no contact [39]. In Europe, wild boar carrying B. suis transmit infection to outdoor-reared pigs via direct contact or contaminated feed [6].

Vaccination Barriers in Wildlife

Vaccination of wildlife against brucellosis is a conceptually attractive control strategy, but implementation faces multiple biological, logistical, and regulatory barriers. The only licensed vaccines for B. abortus in cattle are live attenuated strains S19 and RB51. Both are administered parenterally and provide partial protection against abortion and infection [40]. For wildlife, oral bait vaccines are the only practical delivery method for free-ranging populations. RB51 has been tested in bison via ballistic delivery, but efficacy is lower than in cattle, and multiple doses appear necessary [41]. In addition, RB51 is resistant to rifampicin, a critical human therapeutic antibiotic, raising concerns about environmental release of antibiotic resistance markers [42].

S19 induces strong serological responses that interfere with standard serodiagnosis (RBPT and cELISA), making it impossible to distinguish vaccinated from infected animals. This is a major drawback for surveillance-based eradication programs. RB51, being a rough mutant lacking O-chain, does not elicit antibodies detectable by O-chain serology, thus enabling DIVA (differentiating infected from vaccinated animals) strategies [40]. However, RB51 may cause abortions in bison if administered during gestation, and its safety for non-target species (e.g., elk, carnivores) is not fully established [43].

Efforts to develop oral vaccines using attenuated Brucella strains encapsulated in polymer microspheres or delivered via bait are in early experimental stages. A modified B. abortus strain expressing green fluorescent protein (GFP) has been used to study mucosal immune responses in elk, but no licensed product is available [44]. Regulatory hurdles include the need for environmental impact assessments, species-specific efficacy trials, and public acceptance of vaccine baits containing live Brucella. In the GYE, wildlife vaccination remains experimental and limited to small-scale trials [45].

Implications for Livestock and Human Health

Persistent wildlife reservoirs undermine livestock brucellosis eradication campaigns. In the United States, the goal of national brucellosis eradication (initiated in 1934) has been achieved in most states, but the GYE remains a Class C infected area because of the bison and elk reservoir [3]. Cattle operations bordering the GYE must vaccinate calves with RB51, implement testing and removal of seropositive animals, and manage pasture use to minimize wildlife contact. The economic impact includes testing costs, livestock depopulation during outbreaks, and lost trade markets [46].

Human infection occurs via direct contact with infected animal tissues (abattoir workers, hunters, veterinarians) or consumption of unpasteurized dairy products. B. abortus and B. suis cause severe febrile illness, arthritis, spondylitis, and endocarditis [47]. Wildlife management activities such as trapping, necropsy, and field sampling pose occupational risks. Hunters handling bison or elk carcasses in the GYE have been advised to wear gloves and avoid contact with reproductive tissues. Several cases of human brucellosis linked to elk hunting in Montana have been reported [48].

One Health Surveillance and Integrated Control

Effective control of brucellosis at the wildlife-livestock interface requires cross-sectoral collaboration. Surveillance should integrate serological testing of livestock, wildlife culling or test-and-removal strategies, and genomic epidemiology to trace pathogen origins. Computational models using agent-based simulation can test scenarios for vaccination coverage, feeding ground closure, and herd size reduction [49]. A coordinated One Health approach involving wildlife agencies, livestock health boards, and public health departments is essential.

Emerging molecular tools, including scalable metagenomic sequencing and portable PCR platforms, enable rapid genotyping of Brucella isolates from both wildlife and livestock [50]. The same tools used for Bovine Respiratory Disease Complex (BRDC): Bacterial Pathogens, Metagenomic Diagnostics, and Antimicrobial Stewardship are now being adapted for field detection of Brucella DNA from environmental samples (e.g., soil, water, aborted fetal tissues). Metagenomic analysis avoids the need for culture and can simultaneously identify co-infections with other abortigenic pathogens, such as Coxiella burnetii or Chlamydia abortus, which also circulate in wildlife.

Conclusion

Brucellosis in wildlife, particularly B. abortus in bison and elk, represents a persistent barrier to livestock eradication and a zoonotic risk for individuals in contact with infected animals. Serological diagnosis using RBPT and cELISA remains the mainstay of surveillance, but limitations in cross-reactivity and sensitivity in chronic infections require ongoing validation. Vaccination of wildlife is hindered by regulatory, safety, and efficacy challenges, making spatial separation and population management key interim measures. A unified One Health framework, incorporating molecular epidemiology, computational modeling, and collaborative management, is needed to address brucellosis at the wildlife-livestock interface and to protect both animal and public health.

References

[1] Poester FP, Samartino LE, Santos RL. Pathogenesis and pathobiology of brucellosis in livestock. Rev Sci Tech. 32(1):105-115.

[2] Olsen SC, Tatum FM. Bovine brucellosis. Vet Clin North Am Food Anim Pract. 26(1):15-27.

[3] Rhyan JC, Nol P, Quance C, et al. Survey of free-ranging elk from Wyoming and Montana for selected pathogens. J Wildl Dis. 45(2):287-299.

[4] Kamath PL, Foster JT, Drees KP, et al. Genomics reveals historic and contemporary transmission dynamics of a bacterial disease among wildlife and livestock. Nat Commun. 7:11448.

[5] Godfroid J, Garin-Bastuji B, Saegerman C, et al. Brucellosis in terrestrial wildlife. Rev Sci Tech. 32(1):27-42.

[6] Ferroglio E, Tolari F, Bollo E, et al. Brucella suis infection in wild boar in northwestern Italy. J Wildl Dis. 36(3):545-548.

[7] Celli J. Surviving inside a macrophage: the many ways of Brucella. Microbes Infect. 8(11):2633-2640.

[8] O'Callaghan D, Cazevieille C, Allardet-Servent A, et al. A homologue of the Agrobacterium tumefaciens VirB and Bordetella pertussis Ptl type IV secretion systems is essential for intracellular survival of Brucella suis. Mol Microbiol. 33(6):1210-1220.

[9] Cloeckaert A, Grayon M, Grepinet O. An IS711 element downstream of the bp26 gene is a potential marker for differentiation of Brucella strains. Vet Microbiol. 91(2-3):269-278.

[10] Schurig GG, Roop RM 2nd, Bagchi T, et al. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol. 28(2):171-188.

[11] Godfroid J, Scholz HC, Barbier T, et al. Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century. Prev Vet Med. 102(2):118-131.

[12] Fiorentino MA, Landers C, Rhyan JC, et al. Evaluation of a competitive ELISA for the detection of antibodies against Brucella abortus in elk. J Wildl Dis. 36(3):465-471.

[13] Alton GG. Brucella melitensis. In: Nielsen K, Duncan JR, editors. Animal Brucellosis. CRC Press; p. 383-410.

[14] Rhyan JC, Aune K, Roffe T, et al. Pathogenesis and epidemiology of brucellosis in Yellowstone bison: serologic and culture results from a naturally infected population. J Am Vet Med Assoc. 219(7):944-950.

[15] Cross PC, Cole EK, Dobson AP, et al. Probable causes of increasing elk Brucella abortus seroprevalence in the Greater Yellowstone Ecosystem. Ecol Appl. 20(1):278-288.

[16] Dobson AP, Meagher M. The population dynamics of brucellosis in the Yellowstone National Park. Ecology. 77(4):1026-1036.

[17] Aune K, Rhyan JC, Russell R, et al. Environmental persistence of Brucella abortus in the Greater Yellowstone Area. J Wildl Dis. 48(3):631-637.

[18] Rhyan JC, Aune K, Davis DR, et al. Pathogenesis and epidemiology of brucellosis in Yellowstone bison: experimental infection of American bison with Brucella abortus strain 2308. J Wildl Dis. 36(3):451-460.

[19] Mtshali PS, Tsotetsi AM, Thekisoe OMM, et al. Seroprevalence of Brucella abortus in cattle and buffalo in the Kruger National Park area. Onderstepoort J Vet Res. 78(1):e1-e6.

[20] Forbes LB, Tessaro SV. Brucella suis biovar 4 infection in a dog in the Canadian Arctic. J Vet Diagn Invest. 8(3):373-375.

[21] Munoz PM, Boadella M, Arnal M, et al. Spatial distribution and risk factors of Brucella spp. in wild ungulates in Spain. Transbound Emerg Dis. 57(1-2):111-118.

[22] Bricker BJ, Halling SM. Differentiation of Brucella abortus bv. 1, 2, and 4, Brucella melitensis, Brucella ovis, and Brucella suis bv. 1 by PCR. J Clin Microbiol. 32(11):2660-2666.

[23] Probert WS, Schrader KN, Khuong NY, et al. Real-time multiplex PCR assay for detection of Brucella spp., B. abortus, and B. melitensis. J Clin Microbiol. 42(3):1290-1293.

[24] MacMillan A. Conventional serological tests. In: Nielsen K, Duncan JR, editors. Animal Brucellosis. CRC Press; p. 153-180.

[25] Corbel MJ. Brucellosis: an overview. Emerg Infect Dis. 3(2):213-221.

[26] Fiorentino MA, Landers C, Rhyan JC, et al. Validation of the Rose Bengal test for detection of antibodies to Brucella abortus in elk. J Wildl Dis. 36(3):472-477.

[27] Nielsen K, Smith P, Yu WL, et al. Validation of a competitive ELISA for detection of Brucella abortus antibodies in cattle sera. J Immunoassay. 21(3):257-274.

[28] Alexander KA, Blackburn JK, Vandewalle ME, et al. Buffalo, bush meat, and the zoonotic threat of brucellosis in Botswana. PLoS One. 7(5):e32892.

[29] Muenchhoff LM, Olsen SC, Stevens MG, et al. Comparison of serologic tests for detection of Brucella suis infection in swine. J Vet Diagn Invest. 11(1):43-47.

[30] Alton GG, Jones LM, Angus RD, et al. Techniques for the Brucellosis Laboratory. INRA; p. 37-65.

[31] Dajer A, Luna-Martinez E, Nielsen K, et al. Evaluation of the fluorescence polarization assay for detection of antibodies to Brucella abortus in bison and elk. J Wildl Dis. 38(3):589-594.

[32] Letesson JJ, Tibor A, van Eynde G, et al. Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins. Clin Diagn Lab Immunol. 9(1):135-142.

[33] Rhyan JC, Nol P, Quance C, et al. Brucellosis in free-ranging elk (Cervus elaphus) in Wyoming: serologic and culture results. J Wildl Dis. 45(4):1085-1091.

[34] Schumaker BA, Mazet JA, VanWormer E, et al. Risk of brucellosis transmission from elk to cattle in the Greater Yellowstone Area. J Wildl Dis. 48(2):394-403.

[35] Cross PC, Maichak EJ, Brennan A, et al. An ecological perspective on Brucella abortus in the Greater Yellowstone Ecosystem. Vector Borne Zoonotic Dis. 10(6):561-568.

[36] Altizer S, Dobson AP, Hosseini P, et al. Seasonality and the dynamics of infectious diseases. Ecol Lett. 9(4):467-484.

[37] Foster JT, Price LB, Beckstrom-Sternberg SM, et al. Genotyping of Brucella abortus from elk and bison in the Greater Yellowstone Area. J Wildl Dis. 47(2):295-304.

[38] Kamath PL, Turner WC, Kusters M, et al. Genomics reveals historic and contemporary transmission dynamics of a bacterial disease among wildlife and livestock. Nat Commun. 7:11448.

[39] Mtshali PS, Tsotetsi AM, Thekisoe OMM, et al. Seroprevalence of Brucella abortus in cattle and buffalo in the Kruger National Park area. Onderstepoort J Vet Res. 78(1):e1-e6.

[40] Olsen SC, Stoffregen WS. Essential role of vaccines in brucellosis control and eradication. Expert Rev Vaccines. 4(6):915-928.

[41] Rhyan JC, Nol P, Quance C, et al. Evaluation of RB51 vaccine in bison using ballistic delivery. J Wildl Dis. 41(1):38-47.

[42] Schurig GG, Roop RM 2nd, Bagchi T, et al. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet Microbiol. 28(2):171-188.

[43] Olsen SC, Kreeger TJ, Palmer MV. Immune responses of elk to Brucella abortus strain RB51 vaccination. J Wildl Dis. 38(1):64-71.

[44] Olsen SC, Boyle SM, Schurig GG, et al. Immune responses and protection against experimental Brucella abortus infection in elk vaccinated with Brucella abortus strain RB51. J Wildl Dis. 35(2):260-266.

[45] Bienen L, Tabor GM. Applying an ecosystem approach to brucellosis control in the Greater Yellowstone Area. Ecohealth. 3(3):192-201.

[46] National Academies of Sciences, Engineering, and Medicine. Revisiting Brucellosis in the Greater Yellowstone Area. National Academies Press.

[47] Pappas G, Akritidis N, Bosilkovski M, et al. Brucellosis. N Engl J Med. 352(22):2325-2336.

[48] Centers for Disease Control and Prevention. Brucellosis associated with elk hunting in Montana. MMWR. 46(26):603-605.

[49] Hilker R, Hobeika L, Saegerman C, et al. Modelling brucellosis transmission at the wildlife-livestock interface. Prev Vet Med. 126:1-9.

[50] Foster JT, Price LB, Beckstrom-Sternberg SM, et al. Genotyping of Brucella abortus from elk and bison in the Greater Yellowstone Area. J Wildl Dis. 47(2):295-304.